Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective

Table 1

Dosing schedule and efficacy of secukinumab.

Types of biologics	Dosing schedule [33]	Expected onset of clinical effect (week) [33]	Review of response (week) [33]	Efficacy at week 10 to 16; (PASI 75) [32]	Long-term efficacy [33]
Secukinumab	Subcutaneous, 300mg at week 0, 1, 2, 3, 4 and then every 4 weeks	1	12	90.1%	PASI 75: 88.5%
					PASI 90: 66.4%
					PASI 100: 41.0%